FOXO4-DRI vs Fisetin

How do they actually differ?

Evidence tier: 2 for fisetin mechanism (multi-lab in vitro and animal data); Tier 4 for FOXO4-DRI mechanism (originating-lab proof-of-concept).

Both are described as "senolytics" — agents that selectively eliminate senescent cells, the non-proliferating but metabolically active "zombie cells" that accumulate with age and secrete pro-inflammatory factors collectively called the senescence-associated secretory phenotype. The mechanism stories diverge sharply. FOXO4-DRI is a 47-amino-acid D-retro-inverso peptide engineered to disrupt the FOXO4-p53 protein-protein interaction that senescent cells use to evade apoptosis. By peeling p53 off FOXO4, the peptide allows p53 to drive apoptosis specifically in senescent cells while leaving healthy cells untouched. It is delivered subcutaneously because peptides cannot survive oral digestion intact. Fisetin is a small-molecule flavonoid (3,3',4',7-tetrahydroxyflavone) found naturally in strawberries, apples, onions, and persimmons. Its senolytic action runs through PI3K/AKT inhibition, BCL-2 family modulation, and broad antioxidant activity — multiple targets, lower per-dose potency, but the trade-off is excellent oral bioavailability via supplement-grade capsules. Fisetin is also a generalized polyphenol with anti-inflammatory and possibly direct neuroprotective effects beyond the senolytic mechanism. The matrix has the protocol, dosing, and access detail.

Who should choose FOXO4-DRI?

Evidence tier: 5 — speculative; no human trial data exists. Outside a clinical trial setting, the rational answer is no one.

FOXO4-DRI fits a narrow user profile in 2026: those participating in a clinical trial (none currently registered for the original peptide as of mid-2026), those whose physician has specific clinical reasoning for selecting this molecule over better-evidenced alternatives, or those accepting research-tier risk in pursuit of mechanism-specific selectivity. The peptide's appeal is selectivity — the FOXO4-p53 binding interface is highly specific to senescent cells, which in theory should produce a cleaner safety profile than broader-spectrum senolytics. The Baar 2017 mouse data showed restoration of fur density, kidney function, and treadmill performance in aged mice with no apparent off-target effects. None of this has been replicated in humans, and the originating lab (Peter de Keizer at the Hubrecht Institute) has not published follow-up human work in the eight years since the Cell paper. Research-supplier FOXO4-DRI carries no quality assurance, no purity certificate, and no FDA oversight — the molecule purchased online may or may not be the molecule used in the Baar paper. The honest recommendation in 2026 is that FOXO4-DRI belongs to mechanism-curious users with high risk tolerance and trial-grade clinical supervision, not to general anti-aging consumers. Discuss any consideration with your physician.

Who should choose fisetin?

Evidence tier: 3 — multi-lab animal evidence (Yousefzadeh 2018) plus active Phase 2 human trials at Mayo Clinic and other sites.

Fisetin fits the senolytic-curious general user in 2026 more clearly than any other agent in the class. It is over-the-counter, oral, inexpensive, and supplement-grade widely available. Yousefzadeh 2018 (EBioMedicine) screened ten flavonoids in vitro and identified fisetin as the most potent senolytic; the same paper documented healthspan and lifespan extension in aged mice. The Mayo Clinic group is running Phase 2 trials of fisetin in older adults (frailty, post-COVID symptoms, osteoarthritis, kidney disease, and others) with the senolytic-pulse community protocol of 1500 mg/day across two consecutive days, repeated monthly. At supplement-grade doses, the side-effect profile is mild — some gastrointestinal upset at the high pulse doses; chronic low-dose use as a polyphenol is generally well-tolerated. Patients who want to participate in the senolytic conversation, who have read the Mayo Clinic Phase 2 design, and who accept that human efficacy is not yet established are reasonable fisetin users. Patients with active cancer should avoid the pulse protocol pending oncology consultation. Patients on warfarin, blood thinners, or cytochrome-P450-metabolized medications should discuss interaction risk. Discuss any senolytic consideration with your physician.

What does the evidence base actually say?

Evidence tier: 3 for fisetin (multi-site Phase 2 trials); Tier 4-5 for FOXO4-DRI (single high-impact preclinical paper, no human trials).

Fisetin entered the senolytic conversation through Yousefzadeh 2018 (EBioMedicine), which screened ten flavonoids in cellular senescence assays, identified fisetin as the most potent senolytic, and demonstrated reduction of senescence markers in aged mice and human adipose tissue ex vivo. Multiple independent labs have since reproduced fisetin's senolytic activity in vitro. The Mayo Clinic group (James Kirkland, Tamar Tchkonia, and colleagues) leads the human Phase 2 program covering frailty, kidney disease, osteoarthritis, and post-COVID symptoms with the pulse-dose 20 mg/kg protocol. The Phase 2 readouts have produced mixed but largely positive biomarker signal data with full clinical endpoint readouts staged across 2025-2027. The Dasatinib-plus-Quercetin program (Hickson 2019, Justice 2019) is the comparable small-molecule senolytic story with comparable Phase 2 evidence in diabetic kidney disease and idiopathic pulmonary fibrosis — D+Q is the closest human-tested neighbor to the senolytic conversation. FOXO4-DRI rests on Baar 2017 Cell — one influential paper, well-cited, with limited independent replication beyond the originating de Keizer lab. There are no published Phase 1 or Phase 2 FOXO4-DRI human trials. The peptide remains a mechanism-of-action proof of concept rather than a clinical candidate.

Cost, access, and regulatory comparison

Evidence tier: 2 — supplement and research-supplier pricing reflects April 2026 reality.

Fisetin is supplement-grade in the US, EU, and most jurisdictions worldwide. It is not FDA-approved as a drug; it is regulated as a dietary supplement under DSHEA. Quality varies — third-party-tested products from established supplement brands run $15-40 per month at community-protocol pulse dosing; higher-purity 98%+ products run $80-150. No prescription required, no medical visit required. FOXO4-DRI is research-only worldwide. It is sold by peptide research suppliers as "for research use only" with explicit "not for human consumption" labeling. There is no FDA-approved FOXO4-DRI; there is no compounding pathway because there is no reference drug. The 503A and 503B compounding categories require an FDA-approved drug as the reference; FOXO4-DRI has none. Research-supplier pricing runs ~$400-1,200 per dosing cycle. Quality, purity, and even peptide identity are unverified at the consumer level. Both are off-WADA in athletic competition — neither is on the prohibited list as of 2026, though this could change as the senolytic class develops. See the NIH Clinical Trials registry for active fisetin Phase 2 studies and the Mayo Clinic senolytic research program for ongoing translational work.

Related on Peptide Story

• Longevity pillar guide
• FOXO4-DRI senolytic peptide deep dive
• FOXO4-DRI vs Dasatinib + Quercetin comparison

References

• Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. 2018. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. PMID 30279143
• Baar MP, Brandt RMC, Putavet DA, et al. 2017. Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. Cell. PMID 28340339
• Hickson LJ, Langhi Prata LGP, Bobart SA, et al. 2019. Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. EBioMedicine. PMID 31542391
• Justice JN, Nambiar AM, Tchkonia T, et al. 2019. Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study. EBioMedicine. PMID 30616998